期刊
MINERVA PEDIATRICA
卷 70, 期 3, 页码 252-259出版社
EDIZIONI MINERVA MEDICA
DOI: 10.23736/S0026-4946.16.04368-1
关键词
Palivizumab; Prevention and control; Asthma; Respiratory syncytial virus infections
类别
BACKGROUND: Respiratory syncytial virus (RSV) infection is a disease commonly encountered during childhood and it may relapse. An experience in the early childhood would induce asthma development in the future. Palivizumab has a proven efficacy for the RSV prophylaxis so it may prevent asthma. Our aim was to evaluate the possible protective effect of palivizumab on the development of asthma by using the modified Asthma Predictive Index (mAPI). METHODS: This study's data consist of 339 children between 2 to 5 years of age followed up in healthy children unit from 2008 to 2011. Cases were evaluated in terms of wheezing frequency and characteristic features. Evaluations were performed among three groups; palivizumab-treated children born pretenn (group 1), palivizumab-untreated children born pretenn (group 2) and term newborn children (group 3) with equal number of patients in each group (N.=113). RESULTS: Frequency of the answers about children's experienced wheezing times was significant between groups (P=0.003). A significant difference was found between the groups in terms of the clinician who diagnosed asthma (P=0.045). The groups were compared in terms of the mAPI positivity and a significant difference was found among the groups (P=0.001). Group 1 had lowest and group 3 had highest positivity. Group 1 and group 3 were different (P=0.000), group 2 was found higher than group 1, but was similar to group 3 (P=0.628). CONCLUSIONS: This study supports the benefit of administration of palivizumab to premature children to reduce the risk of asthma development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据